Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge? [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
If you are wondering whether Taysha Gene Therapies at US$6.46 is starting to look expensive or still has room to run, the key question is what the current price implies about the company's underlying value. The stock has been flat over the last week, while the 30 day return is 58.7%, the year to date return is 23.0% and the 1 year return is 258.9%, with a very large 3 year return and a 72.6% decline over 5 years highlighting how quickly sentiment can shift. Recent coverage has focused on Taysha Gene Therapies as a high risk, high reward biotech name, with headlines often highlighting its sharp share price swings and the speculative nature of early stage gene therapy companies. This context is important because it suggests the current price may be reacting as much to changing risk perceptions as to fundamentals. On Simply Wall St's valuation framework, Taysha Gene Therapies has a valuation score of 3 out of 6 . The next step is to look at how different valuation approaches asses
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6GlobeNewswire
- Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingGlobeNewswire
- Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (TSHA) had its price target raised by Canaccord Genuity Group Inc. from $14.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
TSHA
Earnings
- 3/19/26 - Miss
TSHA
Sec Filings
- 4/22/26 - Form ARS
- 4/22/26 - Form DEFA14A
- 4/22/26 - Form DEF
- TSHA's page on the SEC website